Checkpoint Capital L.P.
SAN FRANCISCO, CA
$390m in 6 US stocks at the end of 30 June 2026. The top 10 are 100.0% of the money. It changed about 16.8% of the portfolio this quarter.
Value
$390m
Stocks
6
Top 10 share
100.0%
Turnover
16.8%
What changed this quarter
New
Bought for the first time this quarter.
None this quarter.
Added
Bought more of a stock they already held.
- Revolution MedicinesRVMD19.7% of the fund+56%
- CytokineticsCYTK10.4% of the fund+164%
- Trevi TherapeuticsTRVI0.4% of the fund+50%
Cut
Sold some of their stake.
- Rhythm PharmaceuticalsRYTM33.8% of the fund-3%
- Argenx SEARGX31.3% of the fund-14%
- Disc MedicineIRON4.5% of the fund-16%
Sold out
Sold their entire stake.
- SepternaSEPN-100%
- Crinetics PharmaceuticalsCRNX-100%
Holdings
- Argenx SEARGX
- Share
- 31.3%
- Value
- $122m
- Shares
- 131,283
-14%
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Rhythm PharmaceuticalsRYTM | 33.8% | $132m | 1,186,000 | -3% |
| Argenx SEARGX | 31.3% | $122m | 131,283 | -14% |
| Revolution MedicinesRVMD | 19.7% | $77m | 410,353 | +56% |
| CytokineticsCYTK | 10.4% | $40m | 475,000 | +164% |
| Disc MedicineIRON | 4.5% | $18m | 240,125 | -16% |
| Trevi TherapeuticsTRVI | 0.4% | $1m | 75,000 | +50% |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 81.6% since 30 June 2025.
Where the money is
Health care68.7%
Other31.3%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.